Facebook Is Finally Removing SomeBut Not AllMisleading Preventive HIV Drug Ads
Following pressure from dozens of LGBTQ groups, Facebook is finally pulling down some ads linking the HIV prevention drug Truvada to serious complications like bone and kidney damageads these groups have called false or misleading.
In early December, 50 LGBTQ-affliated groups such as GLAAD issued an open letter to Facebook asking them to remove the ads, after more quiet attempts to convince the social media giant to do so had failed. The ads, which had been circulating for months, were placed by several legal firms looking to solicit clients for potential class action lawsuits against the manufacturers of Truvada, the first drug approved by the Food and Drug Administration for pre-exposure prophylaxis of the HIV-1 virus .
At least one website the ads led consumers to claimed that Truvada could cause an increased risk of bone density problems and kidney failure. But these sorts of claims, the letter and other experts have argued, are largely inaccurate or misrepresentative of the scientific evidence.
Some studies have linked a small increased risk of kidney and bone damage to one of the two drugs used in Truvada, called tenofovir disoproxil.
But these studies have involved people taking tenofovir as a treatment for their existing HIV infection, not as a preventative medication.
Yet despite the lack of any real proof, the ads were already starting to scare people away from trying out PrEP, according to the letter.
Leading public health officials, medical professionals, and dedicated PrEP navigators and outreach coordinators have shared that these advertisements on Facebook and Instagram are being directly cited by at-risk community members expressing heightened fears about taking PrEP, it noted.
If this is their official response, after ignoring us for months, then its a mess, Peter Staley, a long-time HIV/AIDS activist and one of the co-founders of the PrEP4All Collaboration, a organization aiming to cut down the costs of PrEP, told the Post.
We use cookies and analyse traffic to this site. By continuing to use this site, closing this banner, or clicking "I Agree", you agree to the use of cookies. Read our privacy poplicy for more information.